Address: Lek-Sandoz, d.d., Verovškova 57, 1526 Ljubljana

 

Web site: http://www.lek.si/eng/ 

 

The cross-section of the company’s activity and key products: Lek is part of Sandoz, the world’s second-largest pharmaceutical company in the rapidly growing generics industry holding one of the top three places in the key markets (e.g., USA, Germany, France, Russia, etc.). At present, Sandoz offers its products to patients in more than 130 countries around the globe.

 

Lek operates under the umbrella of its parent company Sandoz as:

  • one of its global development centres for products and technologies (medicines to be administered orally, injections),
  • one of global production centres for active pharmaceutical ingredients and medicines (medicines to be administered orally, injections),
  • one of competence centres for vertically integrated products within Sandoz,
  • one of global centres for development and manufacturing of biosimilars within Novartis,
  • the supply centre for the markets of Central and East Europe, South-Eastern Europe and CIS and
  • for selling in the Slovenian market the products from the wide array of Sandoz product portfolio.

 

The product portfolio of Lek focuses on major therapeutic areas: systemic anti-infective medicines, cardiovascular and gastrointestinal systems. In addition, there are blockbusters and niche products made for specific markets in other therapeutic areas.